XML 91 R68.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Combinations (Viropharma,SARcode, Premacure and Lotus) (Details) (USD $)
In Millions, except Per Share data, unless otherwise specified
12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Feb. 12, 2013
Lotus
Dec. 31, 2013
Lotus
Dec. 31, 2012
Lotus
Apr. 17, 2013
SARcode Biosciences Inc
Dec. 31, 2013
SARcode Biosciences Inc
Dec. 31, 2012
SARcode Biosciences Inc
Dec. 31, 2013
SARcode Biosciences Inc
Acquisition and Integration Costs, Gross Amount
Dec. 31, 2013
SARcode Biosciences Inc
Acquisition and Integration Costs, Net Amount
Mar. 08, 2013
Premacure
Dec. 31, 2013
Premacure
Dec. 31, 2012
Premacure
Jan. 24, 2014
Viropharma
Dec. 31, 2013
Viropharma
Dec. 31, 2012
Viropharma
Business Acquisition [Line Items]                                  
Percentage of voting interests acquired       100.00%     100.00%         100.00%          
Cash consideration paid       $ 49.4     $ 151.0         $ 30.6     $ 4,200.0    
Maximum amount of contingent cash consideration       275.0     225.0         169.0          
Integration and acquisition costs (134.1) 13.5 0.1   2.3 0.5     0 5.3 (170.7)   9.5 0   12.8 0
Acquisition-date fair value of consideration totaled       174.2     368.0         140.2          
Fair value of contingent consideration payable       124.8     217.0         109.6          
Net current assets assumed       6.8                          
Net non-current liabilities assumed (including deferred tax liabilities)       63.4     122.4         29.5          
Post acquisition pre-tax losses included in consolidated statement of income               26.0                  
IPR&D       176.7     412.0         151.8          
Goodwill arising on business acquired 170.3 48.1   54.1 54.1   86.6 86.6       29.6          
Net current liabilities assumed             8.2         11.7          
Purchase price paid per share of acquiree (in USD per share)                             $ 50    
Change in fair value of contingent consideration                     $ (176.0)